Clinical Trial Update: IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) [Phase 3]

View source ↗

Summary

A Phase 3 trial (IGNITE) comparing tirabrutinib against Rituximab/Temozolomide for relapsed/refractory primary central nervous system lymphoma is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Rituximab/Temozolomide (rituximab; temozolomide)
• Tirabrutinib (tirabrutinib)

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Relapsed/Refractory Primary Central Nervous System Lymphoma | Phase 3 | Status: RECRUITING